BD Shares Rise on FDA OK for MRSA Test, Stock Upgrade | GenomeWeb
NEW YORK (GenomeWeb News) – Shares of Becton Dickinson rose nearly 4 percent today after the firm announced that the US Food and Drug Administration had cleared its GeneOhm StaphSR assay for identifying Staphylococcus aureus and methicillin-resistant S. aureus from patients with positive blood cultures in around two hours.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.